BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Want to see BMRN full AI Analyst Report?
BMRN Stock Chart & Stats
$54.64
$0.93(1.37%)
At close: 4:00 PM EST
$54.64
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$50.76 - $66.28
Previous CloseN/A
Volume465.01K
Average Volume (3M)1.77M
Market Cap
$10.40B
Enterprise Value$9.73B
Total Cash (Recent Filing)$1.56B
Total Debt (Recent Filing)$642.87M
Price to Earnings (P/E)32.7
Beta0.53
Next Earnings
Aug 04, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.82
Shares Outstanding192,323,360
10 Day Avg. Volume1,498,930
30 Day Avg. Volume1,773,896
Financial Highlights & Ratios
PEG Ratio-1.71
Price to Book (P/B)1.87
Price to Sales (P/S)3.54
P/FCF Ratio15.72
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.02
Enterprise Value/Gross Profit3.92
Enterprise Value/Ebitda16.98
Forecast
1Y Price Target
$93.07Price Target Upside70.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)4.23
Revenue Forecast (FY)$3.62B
Bulls Say, Bears Say
Bulls Say
Acquisition Strengthens PortfolioPlanned acquisition of Amicus expands the enzyme replacement therapy portfolio and reduces competitive exposure for the Voxzogo franchise, supporting a more diversified growth profile.
Clinical Efficacy In Very Young PatientsNew trial data showed statistically significant and sustained improvement in body proportionality for achondroplasia patients who began treatment at a very young age, supporting stronger clinical positioning for earlier intervention.
Market Adoption UpsideLow current penetration among eligible achondroplasia patients indicates substantial runway to increase Voxzogo adoption and expand revenue as more patients start therapy.
Bears Say
Emerging Competitive Pressure From Weekly Injectables And Oral AgentsApproval and advancement of once-weekly injectables and emerging oral FGFR competitors pose layered competitive threats that could erode Voxzogo market share over time.
International Regulatory DependenceHeavy reliance on markets outside the United States makes Voxzogo vulnerable to unfavorable regulatory decisions in Europe, which could materially affect international sales.
Safety Concerns From Slipped Capital Femoral EpiphysisReports of slipped capital femoral epiphysis in investigator-led studies led to discontinuation of several programs and raise safety uncertainty for broader use of the drug.
BioMarin Pharmaceutical News
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $50.76 and its highest was $66.28 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $10.40B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Aug 04, 2026 which is in 91 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on May 04, 2026. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.694 by -$0.154.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.9.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 192,323,360 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of $0.54 in its last earnings report, missing expectations of $0.694. Following the earnings report the stock price went down -0.477%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$93.07 (70.33% Upside)
$93.07 (70.33% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.65%
12-Months-Change
Fundamentals
Return on Equity
5.82%
Trailing 12-Months
Asset Growth
8.66%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by the recent Amicus acquisition, upgraded 2026 revenue guidance (~20% total revenue growth and ~30% Enzyme Therapies growth at midpoint), strong underlying patient demand (Voxzogo patients +20% y/y; Enzyme Therapies +6% y/y), and multiple near‑term clinical catalysts. Near‑term softness in reported Q1 revenue, a $31M one‑time manufacturing charge, higher operating expenses and modest 2026 EPS dilution are notable headwinds, but management attributes much of the revenue softness to order timing and positions acquisition dilution as temporary with accretion expected within 12 months and substantial accretion in 2027. Overall, the positives (deal, guidance lift, patient growth, pipeline milestones) outweigh the one‑time charges and timing issues.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$93.07
▲(70.33% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Ownership Overview
0.50% Insiders
31.44% Mutual Funds
3.39% Other Institutional Investors
43.57% Public Companies and
Individual Investors